Stocks · News reference
Liminatus Pharma Board Adopts Resolutions Approving Reverse Stock Split Of Its Common Stock At Ratio Of 1-For-50
Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company") today announced that its board of directors has adopted resolutions approving a reverse stock split of its common stock, par value
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Veeva Systems (NYSE:VEEV) shares increased by 8.7% to $266.15 during Wednesday's after-market session. The market value of their outstanding shares is at $40.0 billion. The company's, Q2 earnings came
Liminatus Pharma shares are trading lower. The company announced it has engaged Synex Consulting to support the clinical development of IBC101, CD19xCD22 bivalent CAR-T cell therapy candidate.
Liminatus Pharma Engages Synex Consulting To Support Clinical Development Of IBC101, CD19xCD22 Bivalent CAR-T Cell Therapy Candidate